Consequently, CBD is proving to be a leap forward in wellness, showing therapeutic applications in such a variety of facets of human health that it is being suggested that our dietary deficit of cannabinoids during prohibition years is a contributing factor to our illness burden.
CBD is not to be confused with the compounds in cannabis plants which produce the primary psychoactive effects associated with a cannabis high. CBD is virtually undetectable when consumed by humans even in larger quantities. It is valued for therapeutic purposes and for its very low side effect profile.
Global supply of CBD cannot currently meet the enormous demand. Demand is increasing from both a consumer product level as it finds applications in cosmetic and natural wellness industry, as well growing commercial demand from pharmaceutical industry.
Wholesale prices start at the USD$5,000 per kg market. Large industrial buyers pay up to USD$7,000 for pharmaceutical grade.
Our patented method of producing generic cannabidiol using organic chemistry and proprietary biosynthesis technology means larger quantities can be produced faster, cheaper, and independently of seasonal variations, with less environmental impact.
Our target CBD production cost in USD$200 per kg, and first factory has peak output capacity of 360,000kg per year.